Stay updated on IDA53 Clinical Trial
Sign up to get notified when there's something new on the IDA53 Clinical Trial page.

Latest updates to the IDA53 Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe webpage has undergone significant updates, including the introduction of a new clinical trial titled 'IDA53-FILOCLL09', which focuses on the safety and efficacy of combining ibrutinib and daratumumab for treating relapsed or refractory chronic lymphocytic leukemia (CLL) with TP53 dysfunction. Key collaborators and investigators have been named, and the revision number has been updated to v2.15.0.SummaryDifference46%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check56 days agoChange DetectedDifference0.3%
- Check63 days agoChange DetectedDifference0.3%
Stay in the know with updates to IDA53 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IDA53 Clinical Trial page.